Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care.
10.4168/aair.2012.4.4.184
- Author:
David PRICE
1
;
Henry CHRYSTYN
;
Alan KAPLAN
;
John HAUGHNEY
;
Miguel ROMAN-RODRIGUEZ
;
Annie BURDEN
;
Alison CHISHOLM
;
Elizabeth V HILLYER
;
Julie VON ZIEGENWEIDT
;
Muzammil ALI
;
Thys VAN DER MOLEN
Author Information
1. Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK. david@rirl.org
- Publication Type:Original Article
- Keywords:
Asthma;
breath-actuated inhaler;
inhaled corticosteroids;
inhaler device;
pressurised metered-dose inhaler;
short-acting beta2-agonist
- MeSH:
Adrenal Cortex Hormones;
Albuterol;
Anti-Bacterial Agents;
Asthma;
Humans;
Inhalation;
Nebulizers and Vaporizers;
Odds Ratio;
Prescriptions;
Primary Health Care;
Respiratory System;
Retrospective Studies
- From:Allergy, Asthma & Immunology Research
2012;4(4):184-191
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Correct use of inhaler devices is fundamental to effective asthma management but represents an important challenge for patients. The correct inhalation manoeuvre differs markedly for different inhaler types. The objective of this study was to compare outcomes for patients prescribed the same inhaler device versus mixed device types for asthma controller and reliever therapy. METHODS: This retrospective observational study identified patients with asthma (ages 4-80 years) in a large primary care database who were prescribed an inhaled corticosteroid (ICS) for the first time. We compared outcomes for patients prescribed the same breath-actuated inhaler (BAI) for ICS controller and salbutamol reliever versus mixed devices (BAI for controller and pressurised metered-dose inhaler [pMDI] for reliever). The 2-year study included 1 baseline year before the ICS prescription (to identify and correct for confounding factors) and 1 outcome year. Endpoints were asthma control (defined as no hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and severe exacerbations (hospitalisation or oral corticosteroids for asthma). RESULTS: Patients prescribed the same device (n=3,428) were significantly more likely to achieve asthma control (adjusted odds ratio, 1.15; 95% confidence interval [CI], 1.02-1.28) and recorded significantly lower severe exacerbation rates (adjusted rate ratio, 0.79; 95% CI, 0.68-0.93) than those prescribed mixed devices (n=5,452). CONCLUSIONS: These findings suggest that, when possible, the same device should be prescribed for both ICS and reliever therapy when patients are initiating ICS.
